Chemiluminescence Immunoassay Market Synopsis:
Chemiluminescence Immunoassay Market Size Was Valued at USD 5.9 Billion in 2023, and is Projected to Reach USD 9.57 Billion by 2032, Growing at a CAGR of 6% From 2024-2032.
The market for Chemiluminescence Immunoassay (CLIA) is one of the fastest growing analyzers in the diagnostic testing industry that combines the features of immunoassays and chemiluminescent technology. CLIAs are widely applied in the diagnostics of particular protein, hormone, or markers associated with infections, neoplastic diseases, autoimmune diseases, etc. This technology is characterized by high sensitivity and specificity and is appropriate for many applications both in clinical and research practice. Market growth is underlined by the continuously rising need for accurate early diagnosis of diseases, which is important due to the growing number of chronic diseases and the aging population across the world.
Some driving forces for CLIA market are increase in assay technology, increase in the use of fully automated laboratory instruments and emphasis on point of care testing. Automating structure and compatibility with innovative techniques increase the rate and accuracy of assays, making CLIAs the best option in facilities with high turnarounds. Moreover, the Covid-19 pandemic has also surfaced as an agent of change regarding a trusted and effective diagnostic approach that has boosted its demand in both hospital and diagnostic centers. However it is as in the cases where implementation may lead to high initial setup costs and where there is need to recruit specialized personnel to manage complex instruments may limit growth, primarily that which is occurring in emergency economies.
Looking forward, the CLIA market is poised for further expansion as technological innovations continue to improve assay accuracy and reduce turnaround times. Emerging opportunities include expanding applications in companion diagnostics, personalized medicine, and at-home testing kits. The market also sees potential in developing regions where healthcare infrastructure is advancing, increasing access to advanced diagnostic tools. Overall, the CLIA market is set to benefit from both the growing demand for precise diagnostics and ongoing advancements in medical technology.
Chemiluminescence Immunoassay Market Trend Analysis:
Rising Adoption of Automated Chemiluminescence Analyzers
- At present the market for CLIA is admiring a considerable trend towards the automation since the healthcare facilities and laboratories tend to use the chemiluminescence analyzers that are automated. High capacity testing, this reduces human interference and is efficient in a large diagnostic centres and hospitals that deal with massive samples. This shift is made for the faster and more accurate diagnoses particularly since laboratories are constantly striving to cope with the demand for chronic disease testing and other complicated tests.
Expansion of Point-of-Care (POC) Chemiluminescence Testing
- Another well-defined trend in the CLIA market is point-of-care testing or point-of-need testing Point-of-care (POC) testing. Technically advanced and highly portable CLIA formats are being developed for POC using portable and rapid diagnostic methods that can be yielded in outpatient departments, clinics or even home care. This movement is driven by developments in miniaturized assay technology, and increased centrality of near patient testing for results in the context of infections and acute presentations.
Chemiluminescence Immunoassay Market Segment Analysis:
Chemiluminescence Immunoassay Market is Segmented on the basis of Type, Product, Application, End User, and Region.
By Type, High Throughput segment is expected to dominate the market during the forecast period
- The Chemiluminescence Immunoassay (CLIA) market has been divided by type and product. They are high throughput system, medium throughput system and low throughput system based on the volume of tests carried out and their frequency. High throughput systems are used for high throughput screening for faster turnaround time and are best suited to high turnover institution such as hospital and diagnostic centers. While the medium throughput systems provide for an optimal mix of both high unit rate and high testing volume, the low throughput systems are best for low scale testing purposes with specialized use. In relation to products, the market is mainly categorized into reagents, analyzers, and consumables. Some of the assay reagents are important in the assay process; analyzers offer the instruments required to assess the tests results; the consumables in this process comprise of the testing materials including the sample tubes and test kits among others. In combination, these segments directly contribute to investments in the progression of the CLIA market while addressing various diagnostic requirements in multiple setting types.
By Application, Oncology and Endocrinology segment expected to held the largest share
- The Chemiluminescence Immunoassay (CLIA) is an important market of diagnostic systems used for the diagnosis of various pathological conditions across different therapeutic areas and specialty markets, namely oncology, endocrinology, hepatitis, retroviruses, cardiac markers, infectious diseases, bone and mineral disorders, autoimmune diseases, allergies, stool testing and screen, drug discovery and development. It is led by the rising need to diagnose diseases quickly, precisely, and at high sensitivity using biomarkers to identify such diseases. To sum up, CLIA allows receiving highly accurate results with limited sample volume and can be beneficial for both ordinary clinical practice and innovative investigations, concerning the theoretic and practical foundation of the advanced trend of individualized medicine. Over the years, the growth on assay technologies has led to innovation on the test kits, automation and multiplexing which has futher opened up the market to hi-tech health care and pharmaceutical industries.
Chemiluminescence Immunoassay Market Regional Insights:
North America is Expected to Dominate the Market Over the Forecast period
- In terms of revenue, North America will account for the highest market share in the global chemiluminescence immunoassay (CLIA) market during the forecast period, owing to improved diagnostics industry standards, elevated demand for early diagnosis products, and robust centers for healthcare. The large number of key market players and the continually increasing requirement for accurate diagnostics in clinics and research are driving the market. Also, the rise of chronic diseases, the growth of personalized medicine has created additional opportunities for the CLIA mediated testing solutions in North American market.
Active Key Players in the Chemiluminescence Immunoassay Market:
- Siemens AG (Germany)
- Abbott Laboratories (United States)
- F. Hoffmann-La Roche Ltd. (Switzerland)
- Danaher Corporation (United States)
- bioMérieux SA (France)
- Johnson & Johnson (United States)
- Tosoh Corporation (Japan)
- Randox Laboratories (United Kingdom)
- DiaSorin S.p.A. (Italy)
- PerkinElmer, Inc. (United States)
- Mindray Bio-Medical Electronics Co., Ltd. (China)
- Getein Biotech, Inc. (China)
- QuidelOrtho Corporation (United States)
- Sysmex Corporation (Japan)
- Ortho Clinical Diagnostics (United States)
- Abcam plc (United Kingdom)
- Thermo Fisher Scientific Inc. (United States)
- Hologic, Inc. (United States)
- Other Active Players
|
Global Chemiluminescence Immunoassay Market |
|||
|
Base Year: |
2023 |
Forecast Period: |
2024-2032 |
|
Historical Data: |
2017 to 2023 |
Market Size in 2023: |
USD 5.9 Billion |
|
Forecast Period 2024-32 CAGR: |
6% |
Market Size in 2032: |
USD 9.57 Billion |
|
Segments Covered: |
By Type |
|
|
|
By Product |
|
||
|
Application |
|
||
|
By End User |
|
||
|
By Region |
|
||
|
Key Market Drivers: |
|
||
|
Key Market Restraints: |
|
||
|
Key Opportunities: |
|
||
|
Companies Covered in the report: |
|
||
1.1 Scope and Coverage
Chapter 2:Executive Summary
Chapter 3: Market Landscape
3.1 Market Dynamics
3.1.1 Drivers
3.1.2 Restraints
3.1.3 Opportunities
3.1.4 Challenges
3.2 Market Trend Analysis
3.3 PESTLE Analysis
3.4 Porter's Five Forces Analysis
3.5 Industry Value Chain Analysis
3.6 Ecosystem
3.7 Regulatory Landscape
3.8 Price Trend Analysis
3.9 Patent Analysis
3.10 Technology Evolution
3.11 Investment Pockets
3.12 Import-Export Analysis
Chapter 4: Chemiluminescence Immunoassay Market by By Type (2018-2032)
4.1 Chemiluminescence Immunoassay Market Snapshot and Growth Engine
4.2 Market Overview
4.3 High Throughput
4.3.1 Introduction and Market Overview
4.3.2 Historic and Forecasted Market Size in Value USD and Volume Units
4.3.3 Key Market Trends, Growth Factors, and Opportunities
4.3.4 Geographic Segmentation Analysis
4.4 Medium Throughput
4.5 Low Throughput
Chapter 5: Chemiluminescence Immunoassay Market by By Product (2018-2032)
5.1 Chemiluminescence Immunoassay Market Snapshot and Growth Engine
5.2 Market Overview
5.3 Reagents
5.3.1 Introduction and Market Overview
5.3.2 Historic and Forecasted Market Size in Value USD and Volume Units
5.3.3 Key Market Trends, Growth Factors, and Opportunities
5.3.4 Geographic Segmentation Analysis
5.4 Analyser
5.5 Consumables
5.6 Application
5.7 Oncology and Endocrinology
5.8 Hepatitis and Retroviruses
5.9 Cardiac Markers
5.10 Infectious Disease
5.11 Bone and Mineral Disorders
5.12 Auto-Immune Diseases
5.13 Allergy
5.14 Stool Testing
5.15 Drug Discovery and Development
Chapter 6: Chemiluminescence Immunoassay Market by By End User (2018-2032)
6.1 Chemiluminescence Immunoassay Market Snapshot and Growth Engine
6.2 Market Overview
6.3 Hospitals and Clinics
6.3.1 Introduction and Market Overview
6.3.2 Historic and Forecasted Market Size in Value USD and Volume Units
6.3.3 Key Market Trends, Growth Factors, and Opportunities
6.3.4 Geographic Segmentation Analysis
6.4 Medical and Diagnostic Laboratories
6.5 Pharmaceutical Companies
Chapter 7: Company Profiles and Competitive Analysis
7.1 Competitive Landscape
7.1.1 Competitive Benchmarking
7.1.2 Chemiluminescence Immunoassay Market Share by Manufacturer (2024)
7.1.3 Industry BCG Matrix
7.1.4 Heat Map Analysis
7.1.5 Mergers and Acquisitions
7.2 SIEMENS AG (GERMANY)
7.2.1 Company Overview
7.2.2 Key Executives
7.2.3 Company Snapshot
7.2.4 Role of the Company in the Market
7.2.5 Sustainability and Social Responsibility
7.2.6 Operating Business Segments
7.2.7 Product Portfolio
7.2.8 Business Performance
7.2.9 Key Strategic Moves and Recent Developments
7.2.10 SWOT Analysis
7.3 ABBOTT LABORATORIES (UNITED STATES)
7.4 F. HOFFMANN-LA ROCHE LTD. (SWITZERLAND)
7.5 DANAHER CORPORATION (UNITED STATES)
7.6 BIOMÉRIEUX SA (FRANCE)
7.7 JOHNSON & JOHNSON (UNITED STATES)
7.8 TOSOH CORPORATION (JAPAN)
7.9 RANDOX LABORATORIES (UNITED KINGDOM)
7.10 DIASORIN S.P.A. (ITALY)
7.11 PERKINELMER INC. (UNITED STATES)
7.12 MINDRAY BIO-MEDICAL ELECTRONICS CO. LTD. (CHINA)
7.13 GETEIN BIOTECH INC. (CHINA)
7.14 QUIDELORTHO CORPORATION (UNITED STATES)
7.15 SYSMEX CORPORATION (JAPAN)
7.16 ORTHO CLINICAL DIAGNOSTICS (UNITED STATES)
7.17 ABCAM PLC (UNITED KINGDOM)
7.18 THERMO FISHER SCIENTIFIC INC. (UNITED STATES)
7.19 HOLOGIC INC. (UNITED STATES)
7.20 OTHER ACTIVE PLAYERS
Chapter 8: Global Chemiluminescence Immunoassay Market By Region
8.1 Overview
8.2. North America Chemiluminescence Immunoassay Market
8.2.1 Key Market Trends, Growth Factors and Opportunities
8.2.2 Top Key Companies
8.2.3 Historic and Forecasted Market Size by Segments
8.2.4 Historic and Forecasted Market Size By By Type
8.2.4.1 High Throughput
8.2.4.2 Medium Throughput
8.2.4.3 Low Throughput
8.2.5 Historic and Forecasted Market Size By By Product
8.2.5.1 Reagents
8.2.5.2 Analyser
8.2.5.3 Consumables
8.2.5.4 Application
8.2.5.5 Oncology and Endocrinology
8.2.5.6 Hepatitis and Retroviruses
8.2.5.7 Cardiac Markers
8.2.5.8 Infectious Disease
8.2.5.9 Bone and Mineral Disorders
8.2.5.10 Auto-Immune Diseases
8.2.5.11 Allergy
8.2.5.12 Stool Testing
8.2.5.13 Drug Discovery and Development
8.2.6 Historic and Forecasted Market Size By By End User
8.2.6.1 Hospitals and Clinics
8.2.6.2 Medical and Diagnostic Laboratories
8.2.6.3 Pharmaceutical Companies
8.2.7 Historic and Forecast Market Size by Country
8.2.7.1 US
8.2.7.2 Canada
8.2.7.3 Mexico
8.3. Eastern Europe Chemiluminescence Immunoassay Market
8.3.1 Key Market Trends, Growth Factors and Opportunities
8.3.2 Top Key Companies
8.3.3 Historic and Forecasted Market Size by Segments
8.3.4 Historic and Forecasted Market Size By By Type
8.3.4.1 High Throughput
8.3.4.2 Medium Throughput
8.3.4.3 Low Throughput
8.3.5 Historic and Forecasted Market Size By By Product
8.3.5.1 Reagents
8.3.5.2 Analyser
8.3.5.3 Consumables
8.3.5.4 Application
8.3.5.5 Oncology and Endocrinology
8.3.5.6 Hepatitis and Retroviruses
8.3.5.7 Cardiac Markers
8.3.5.8 Infectious Disease
8.3.5.9 Bone and Mineral Disorders
8.3.5.10 Auto-Immune Diseases
8.3.5.11 Allergy
8.3.5.12 Stool Testing
8.3.5.13 Drug Discovery and Development
8.3.6 Historic and Forecasted Market Size By By End User
8.3.6.1 Hospitals and Clinics
8.3.6.2 Medical and Diagnostic Laboratories
8.3.6.3 Pharmaceutical Companies
8.3.7 Historic and Forecast Market Size by Country
8.3.7.1 Russia
8.3.7.2 Bulgaria
8.3.7.3 The Czech Republic
8.3.7.4 Hungary
8.3.7.5 Poland
8.3.7.6 Romania
8.3.7.7 Rest of Eastern Europe
8.4. Western Europe Chemiluminescence Immunoassay Market
8.4.1 Key Market Trends, Growth Factors and Opportunities
8.4.2 Top Key Companies
8.4.3 Historic and Forecasted Market Size by Segments
8.4.4 Historic and Forecasted Market Size By By Type
8.4.4.1 High Throughput
8.4.4.2 Medium Throughput
8.4.4.3 Low Throughput
8.4.5 Historic and Forecasted Market Size By By Product
8.4.5.1 Reagents
8.4.5.2 Analyser
8.4.5.3 Consumables
8.4.5.4 Application
8.4.5.5 Oncology and Endocrinology
8.4.5.6 Hepatitis and Retroviruses
8.4.5.7 Cardiac Markers
8.4.5.8 Infectious Disease
8.4.5.9 Bone and Mineral Disorders
8.4.5.10 Auto-Immune Diseases
8.4.5.11 Allergy
8.4.5.12 Stool Testing
8.4.5.13 Drug Discovery and Development
8.4.6 Historic and Forecasted Market Size By By End User
8.4.6.1 Hospitals and Clinics
8.4.6.2 Medical and Diagnostic Laboratories
8.4.6.3 Pharmaceutical Companies
8.4.7 Historic and Forecast Market Size by Country
8.4.7.1 Germany
8.4.7.2 UK
8.4.7.3 France
8.4.7.4 The Netherlands
8.4.7.5 Italy
8.4.7.6 Spain
8.4.7.7 Rest of Western Europe
8.5. Asia Pacific Chemiluminescence Immunoassay Market
8.5.1 Key Market Trends, Growth Factors and Opportunities
8.5.2 Top Key Companies
8.5.3 Historic and Forecasted Market Size by Segments
8.5.4 Historic and Forecasted Market Size By By Type
8.5.4.1 High Throughput
8.5.4.2 Medium Throughput
8.5.4.3 Low Throughput
8.5.5 Historic and Forecasted Market Size By By Product
8.5.5.1 Reagents
8.5.5.2 Analyser
8.5.5.3 Consumables
8.5.5.4 Application
8.5.5.5 Oncology and Endocrinology
8.5.5.6 Hepatitis and Retroviruses
8.5.5.7 Cardiac Markers
8.5.5.8 Infectious Disease
8.5.5.9 Bone and Mineral Disorders
8.5.5.10 Auto-Immune Diseases
8.5.5.11 Allergy
8.5.5.12 Stool Testing
8.5.5.13 Drug Discovery and Development
8.5.6 Historic and Forecasted Market Size By By End User
8.5.6.1 Hospitals and Clinics
8.5.6.2 Medical and Diagnostic Laboratories
8.5.6.3 Pharmaceutical Companies
8.5.7 Historic and Forecast Market Size by Country
8.5.7.1 China
8.5.7.2 India
8.5.7.3 Japan
8.5.7.4 South Korea
8.5.7.5 Malaysia
8.5.7.6 Thailand
8.5.7.7 Vietnam
8.5.7.8 The Philippines
8.5.7.9 Australia
8.5.7.10 New Zealand
8.5.7.11 Rest of APAC
8.6. Middle East & Africa Chemiluminescence Immunoassay Market
8.6.1 Key Market Trends, Growth Factors and Opportunities
8.6.2 Top Key Companies
8.6.3 Historic and Forecasted Market Size by Segments
8.6.4 Historic and Forecasted Market Size By By Type
8.6.4.1 High Throughput
8.6.4.2 Medium Throughput
8.6.4.3 Low Throughput
8.6.5 Historic and Forecasted Market Size By By Product
8.6.5.1 Reagents
8.6.5.2 Analyser
8.6.5.3 Consumables
8.6.5.4 Application
8.6.5.5 Oncology and Endocrinology
8.6.5.6 Hepatitis and Retroviruses
8.6.5.7 Cardiac Markers
8.6.5.8 Infectious Disease
8.6.5.9 Bone and Mineral Disorders
8.6.5.10 Auto-Immune Diseases
8.6.5.11 Allergy
8.6.5.12 Stool Testing
8.6.5.13 Drug Discovery and Development
8.6.6 Historic and Forecasted Market Size By By End User
8.6.6.1 Hospitals and Clinics
8.6.6.2 Medical and Diagnostic Laboratories
8.6.6.3 Pharmaceutical Companies
8.6.7 Historic and Forecast Market Size by Country
8.6.7.1 Turkiye
8.6.7.2 Bahrain
8.6.7.3 Kuwait
8.6.7.4 Saudi Arabia
8.6.7.5 Qatar
8.6.7.6 UAE
8.6.7.7 Israel
8.6.7.8 South Africa
8.7. South America Chemiluminescence Immunoassay Market
8.7.1 Key Market Trends, Growth Factors and Opportunities
8.7.2 Top Key Companies
8.7.3 Historic and Forecasted Market Size by Segments
8.7.4 Historic and Forecasted Market Size By By Type
8.7.4.1 High Throughput
8.7.4.2 Medium Throughput
8.7.4.3 Low Throughput
8.7.5 Historic and Forecasted Market Size By By Product
8.7.5.1 Reagents
8.7.5.2 Analyser
8.7.5.3 Consumables
8.7.5.4 Application
8.7.5.5 Oncology and Endocrinology
8.7.5.6 Hepatitis and Retroviruses
8.7.5.7 Cardiac Markers
8.7.5.8 Infectious Disease
8.7.5.9 Bone and Mineral Disorders
8.7.5.10 Auto-Immune Diseases
8.7.5.11 Allergy
8.7.5.12 Stool Testing
8.7.5.13 Drug Discovery and Development
8.7.6 Historic and Forecasted Market Size By By End User
8.7.6.1 Hospitals and Clinics
8.7.6.2 Medical and Diagnostic Laboratories
8.7.6.3 Pharmaceutical Companies
8.7.7 Historic and Forecast Market Size by Country
8.7.7.1 Brazil
8.7.7.2 Argentina
8.7.7.3 Rest of SA
Chapter 9 Analyst Viewpoint and Conclusion
9.1 Recommendations and Concluding Analysis
9.2 Potential Market Strategies
Chapter 10 Research Methodology
10.1 Research Process
10.2 Primary Research
10.3 Secondary Research
|
Global Chemiluminescence Immunoassay Market |
|||
|
Base Year: |
2023 |
Forecast Period: |
2024-2032 |
|
Historical Data: |
2017 to 2023 |
Market Size in 2023: |
USD 5.9 Billion |
|
Forecast Period 2024-32 CAGR: |
6% |
Market Size in 2032: |
USD 9.57 Billion |
|
Segments Covered: |
By Type |
|
|
|
By Product |
|
||
|
Application |
|
||
|
By End User |
|
||
|
By Region |
|
||
|
Key Market Drivers: |
|
||
|
Key Market Restraints: |
|
||
|
Key Opportunities: |
|
||
|
Companies Covered in the report: |
|
||
Frequently Asked Questions :
The forecast period in the Chemiluminescence Immunoassay Market research report is 2024-2032.
Siemens AG (Germany), Abbott Laboratories (United States), F. Hoffmann-La Roche Ltd. (Switzerland), Danaher Corporation (United States), bioMérieux SA (France), Johnson & Johnson (United States), Tosoh Corporation (Japan), Randox Laboratories (United Kingdom), DiaSorin S.p.A. (Italy), PerkinElmer, Inc. (United States), Mindray Bio-Medical Electronics Co., Ltd. (China), Getein Biotech, Inc. (China), QuidelOrtho Corporation (United States), Sysmex Corporation (Japan), Ortho Clinical Diagnostics (United States), Abcam plc (United Kingdom), Thermo Fisher Scientific Inc. (United States), Hologic, Inc. (United States), and Other Active Players.
The Chemiluminescence Immunoassay Market is segmented into By Type, Product, Application, End User and region. By Type (High Throughput, Medium Throughput and Low Throughput), Product (Reagents, Analyser and Consumables), Application (Oncology and Endocrinology, Hepatitis and Retroviruses, Cardiac Markers, Infectious Disease, Bone and Mineral Disorders, Auto-Immune Diseases, Allergy, Stool Testing, Drug Discovery and Development), End User (Hospitals and Clinics, Medical and Diagnostic Laboratories, Pharmaceutical Companies). By region, it is analyzed across North America (U.S., Canada, Mexico), Eastern Europe (Russia, Bulgaria, The Czech Republic, Hungary, Poland, Romania, Rest of Eastern Europe), Western Europe (Germany, UK, France, The Netherlands, Italy, Spain, Rest of Western Europe), Asia Pacific (China, India, Japan, South Korea, Malaysia, Thailand, Vietnam, The Philippines, Australia, New-Zealand, Rest of APAC), Middle East & Africa (Turkiye, Bahrain, Kuwait, Saudi Arabia, Qatar, UAE, Israel, South Africa), South America (Brazil, Argentina, Rest of SA).
Chemiluminescence Immunoassay (CLIA) is a highly sensitive and specific laboratory technique used to detect and measure substances, such as hormones, proteins, or infectious agents, in biological samples. It combines the principles of immunoassay, where antibodies bind to target molecules, with chemiluminescence, where a chemical reaction produces light. The intensity of the emitted light is proportional to the concentration of the target analyte in the sample. CLIA is widely used in diagnostics, particularly for detecting low levels of biomarkers, offering advantages such as high sensitivity, precision, and faster turnaround times compared to traditional methods like enzyme-linked immunosorbent assay (ELISA).
Chemiluminescence Immunoassay Market Size Was Valued at USD 5.9 Billion in 2023, and is Projected to Reach USD 9.57 Billion by 2032, Growing at a CAGR of 6% From 2024-2032.
